A Phase 1 Open-label, Multicenter Study Evaluating theSafety and Efficacy of KITE-363 or KITE-753, AutologousAnti-CD19/CD20 CAR T-cell Therapies, in Subjects WithRelapsed and/or Refractory B-cell Lymphoma

Contact:

212-342-5162

NCT Number:

NCT04989803(link is external and opens in a new window)

Protocol:

AAAU5501

Study Status:

Active/Enrolling

Population:

Adult

Phase:

I

You have been invited to participate in this study because you have relapsed and/or refractory B-cell lymphoma and standard therapies available to treat your disease have limited effectiveness. The purpose of this study is to find out if the experimental products, KITE-363 and KITE-753, are safe and effective in treating your relapsed and/or refractory B-cell lymphoma. Participants will receive either KITE-363 or KITE-753 one time through into the vein (IV) infusion. The experimental treatment would involve removing some of your immune cells, genetically engineering those cells to identify cancer, receiving additional therapy while you wait for those cells to be released, and then infusing those cells back and assessing the effect on your cancer cells. This is the first time KITE-363 and KITE-753 are being used in humans.

Are you Eligible? (Inclusion Criteria)

  • You must be 18 years or older - Have been diagnosed with B-cell lymphoma - Have relapsed after, or are refractory to, other standard of care treatments

Specialty Area(s)

Lymphoma, Non-Hodgkin's Lymphoma, Immunotherapy

Principal Investigator

Ran Reshef, MD, MSc

Profile Headshot
  • Director of Translational Research, Blood and Marrow Transplantation Program
  • Director of the Cell Therapy Program

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
Open location in Google Maps